BRIEF published on 10/08/2026 at 08:35, 24 days 5 hours ago GenSight Biologics and National Hospital Publish GS030 Trial Outcomes Gene Therapy GenSight Biologics Optogenetics Retinitis Pigmentosa GS030 PIONEER Trial
BRIEF published on 10/08/2026 at 08:35, 24 days 5 hours ago Publication of the results of the GS030 trial for retinitis pigmentosa Gene Therapy GenSight Biologics Optogenetics Retinitis Pigmentosa Trial Results
PRESS RELEASE published on 10/08/2026 at 08:30, 24 days 5 hours ago Inside Information / Other news releases GenSight Biologics and 15-20 National Hospital publish NEJM article on GS030 Phase 1/2 trial results for retinitis pigmentosa treatment, showcasing promising optogenetics approach GenSight Biologics Optogenetics 15-20 National Hospital NEJM Article GS030
BRIEF published on 10/08/2026 at 07:05, 24 days 6 hours ago GenSight Biologics Secures €1 Million Funding from Shareholders Shareholders Fundraising Financial Strategy GenSight Biologics Retinal Therapies
PRESS RELEASE published on 10/08/2026 at 07:00, 24 days 6 hours ago Inside Information / Other news releases GenSight Biologics successfully completes €1.0 million fundraising subscribed by existing shareholders. Proceeds to be used for operational activities and working capital requirements Shareholders Working Capital Fundraising Operational Activities GenSight Biologics
BRIEF published on 10/08/2026 at 01:06, 24 days 12 hours ago Financial position of GenSight Biologics as of September 30, 2026 Treasury Bridge Financing GenSight Biologics Phase III RECOVER Access Programs
BRIEF published on 09/30/2026 at 00:42, 1 month 1 day ago GenSight Biologics Reports 2026 Interim Financial Results Funding Challenges GenSight Biologics Early Access Programs Financial Results 2026 Clinical Trials Update
PRESS RELEASE published on 09/30/2026 at 00:37, 1 month 1 day ago Inside Information / News release on accounts, results GenSight Biologics reports interim financial results for the first half of 2026, including revenue of €(1.2) million, highlighting successful manufacturing technology transfer and progress in clinical studies Revenue Clinical Studies GenSight Biologics Interim Financial Results Manufacturing Technology Transfer
BRIEF published on 09/08/2026 at 07:35, 1 month 23 days ago GenSight Biologics: Review and Outlook as of September 2026 GenSight Biologics Gene Therapies REVISED STUDY LUMEVOQ® Manufacturing Access Programs
PRESS RELEASE published on 09/08/2026 at 07:30, 1 month 23 days ago Inside Information / Other news releases GenSight Biologics provides business updates on manufacturing, clinical activities, and financial status for September 2026, including progress on gene therapy treatments Financial Updates Manufacturing Business Updates Clinical Activities GenSight Biologics
Published on 10/30/2026 at 23:35, 1 day 14 hours ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 1 day 14 hours ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 1 day 18 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 1 day 22 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 11/01/2026 at 10:35, 2 hours 59 minutes ago Shenzhen Unveils APEC China 2026 Host-City Theme Song and Music Video
Published on 11/01/2026 at 05:00, 8 hours 34 minutes ago 2026 Yangtze River Culture Festival Opens in Yonglian Village, Zhangjiagang, Jiangsu
Published on 10/31/2026 at 16:35, 20 hours 59 minutes ago SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 1 day 14 hours ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 23:00, 1 day 14 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 12:00, 2 days 1 hour ago Capital increase through exercise of subscription rights
